---
schema_version: "secwatch.filing_event.v1"
accession: "0001847903-24-000126"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:49:56.497806+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Centessa Q2 net loss widens to $43.8M; cash $294.8M; ORX750 data expected 2H 2024

## Summary
- Net loss $43.8M vs $24.9M YoY; prior Q2 included $24.1M tax benefit.
- Cash $294.8M; funds operations into mid-2026; raised $107.3M net in public offering.
- ORX750 Phase 1 initiated; PoC data in sleep-deprived volunteers expected 2H 2024 using MWT.
- ORX142 nominated as development candidate; IND-enabling activities underway.
- SerpinPC registrational program progressing; PRESent-2 Part 1 interim analysis planned 2024.

## SEC filing metadata
- accession: 0001847903-24-000126
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000184790324000126/0001847903-24-000126-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000184790324000126/cnta-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001847903-24-000126
- JSON: https://secwatch.observer/filing/0001847903-24-000126.json
- Plain text: https://secwatch.observer/filing/0001847903-24-000126.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.